Healthcare IT and Services

NeuroVive

May 2015

BUYER

US institutional investors.

TARGET

NeuroVive Pharmaceutical (publ) is a leading mitochondrial medicine company, engaged in the development of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. The addressable medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s share is listed on Nasdaq, Stockholm.

TRANSACTION

Directed issue to a number of US institutional investors of SEK 70 million to fund the commercialization and further development of NeuroVive’s product portfolio.

Prev Next View all transactions
Cookies

This website is using cookiesfor statistics and user experience

This website uses cookies to improve your user experience, to provide a basis for improvement and further development of the website and to be able to direct more relevant offers to you.

Feel free to read ours privacy policy. If you agree to our use, choose Accept all. If you want to change your choice afterwards, you will find that option at the bottom of the page.